Kalaris Therapeutics says Phase 1b/2 neovascular AMD trial of TH103 is enrolling, with initial data expected in 1H 2027
Kalaris Therapeutics Inc. operates as a pharmaceutical enterprise. The company's core mission centers on developing innovative cell therapies. These treatments are designed to reactivate the body's inherent immunity against critical, virus-linked diseases, especially in patients with profoundly compromised immune systems.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | $165.00K | $1.14M |
| Cost of Revenue | N/A | N/A | N/A | $1.12M | $73.00K | $165.00K | $1.14M |
| Gross Profit | N/A | N/A | N/A | $-1.12M | $-73.00K | N/A | N/A |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $55.26M | $13.46M | $14.01M | $168.70M | $71.24M | $26.70M | $3.60M |
| Operating Income | $-55.26M | $-13.46M | $-14.01M | $-169.82M | $-71.31M | $-26.70M | $-3.60M |
| Operating Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -16182.42% | -316.83% |
| Net Income | $-58.77M | $-14.70M | $-15.48M | $-171.96M | $-69.78M | $-23.84M | $-2.43M |
| Net Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -14447.88% | -214.10% |
| EPS (Basic) | $-11.73 | $-42.09 | $-50.62 | $-63.00 | $-59.67 | $-8.42 | $-2.88 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |